{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:55:00Z","timestamp":1790895300344,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>The peripheral vessel tortuosity index (TI) was proposed to discriminate procedural success in patients undergoing transcatheter endovascular aortic replacement but not in those undergoing transcatheter aortic valve implantation (TAVI). We aimed to investigate the TI and its prognostic relevance in patients undergoing transfemoral (Tf) TAVI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective, observational single-center study, including patients undergoing Tf-TAVI from April 2011 to January 2023 at the TUM University Hospital, German Heart Centre, and available computed tomography angiography (CTA). Peripheral vessel measurements were performed using dedicated software (3mensio, Pie Medical). TI was determined dividing true central lumen vessel length from centerline reconstruction and direct distance from the aorto-iliac bifurcation to the epigastric artery. TI was dichotomized based on severity according to EVAR guidelines, where a TI of 1.5 is considered discriminatory for nonsevere tortuosity [&lt;\u20091.5 for low TI (LTI)] and\u2009&gt;\u20091.5 for high TI (HTI)]. Valve Academic Research Consortium 3 definitions were applied to describe procedural and follow-up outcomes. Mortality at 6-month follow-up was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included 2002 patients. Overall age was 81\u00a0years [77, 85], 45.2% were female, EuroScore II was 4.22 [2.39, 7.60]. Age (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), female sex (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), diabetes (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), peripheral artery disease (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002), myocardial infarction (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.013), and creatinine (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) were associated with tortuosity. Adjusted 6-month analysis showed that TI\u2009&gt;\u20091.50 was associated with increased mortality [hazard ratio (HR) 1.679, 95% CI (1.098\u20132.567),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.017].\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TI\u2009&gt;\u20091.50 may determine a higher-risk population in patients undergoing Tf-TAVI. Further study is required to validate our findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                    <jats:p>Tortuosity index as a risk factor for mortality at 6\u00a0months after transcatheter aortic valve implantation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-026-03035-w","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:57:42Z","timestamp":1790848662000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Peripheral vessel tortuosity index and prognosis in patients undergoing transcatheter aortic valve implantation"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0505-9530","authenticated-orcid":false,"given":"Hector A.","family":"Alvarez-Covarrubias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Jurisic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Seguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Salzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Hug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"H\u00fcbner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Starnecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Syryca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinand","family":"Haug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costanza","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Rheude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Patrick","family":"Mayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Cassese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Kastrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erion","family":"Xhepa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Joner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"15","key":"3035_CR1","doi-asserted-by":"publisher","first-page":"e1549","DOI":"10.4244\/EIJ-D-18-01010","volume":"14","author":"E Holger","year":"2019","unstructured":"Holger E, Rajendra HM (2019) Transcatheter aortic valve implantation (TAVI) in Germany: more than 100,000 procedures and now the standard of care for the elderly. EuroIntervention 14(15):e1549\u2013e1552","journal-title":"EuroIntervention"},{"issue":"21","key":"3035_CR2","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/j.jacc.2020.09.595","volume":"76","author":"JD Carroll","year":"2020","unstructured":"Carroll JD, Mack MJ, Vemulapalli S, Herrmann HC, Gleason TG, Hanzel G et al (2020) STS-ACC TVT registry of transcatheter aortic valve replacement. J Am Coll Cardiol 76(21):2492\u20132516","journal-title":"J Am Coll Cardiol"},{"issue":"26","key":"3035_CR3","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1056\/NEJMsa1901109","volume":"380","author":"S Vemulapalli","year":"2019","unstructured":"Vemulapalli S, Carroll JD, Mack MJ, Li Z, Dai D, Kosinski AS et al (2019) Procedural volume and outcomes for transcatheter aortic-valve replacement. N Engl J Med 380(26):2541\u20132550","journal-title":"N Engl J Med"},{"issue":"4","key":"3035_CR4","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jcin.2022.12.009","volume":"16","author":"T Palmerini","year":"2023","unstructured":"Palmerini T, Saia F, Kim WK, Renker M, Iadanza A, Fineschi M et al (2023) Vascular access in patients with peripheral arterial disease undergoing TAVR: the Hostile Registry. JACC Cardiovasc Interv 16(4):396\u2013411","journal-title":"JACC Cardiovasc Interv"},{"issue":"3","key":"3035_CR5","first-page":"628","volume":"101","author":"HA Alvarez-Covarrubias","year":"2023","unstructured":"Alvarez-Covarrubias HA, Joner M, Cassese S, Warmbrunn M, Lutz J, Trenkwalder T et al (2023) Iliofemoral artery predilation prior to transfemoral transcatheter aortic valve implantation in patients with aortic valve stenosis and advanced peripheral artery disease. Catheter Cardiovasc Interv 101(3):628\u2013638","journal-title":"Catheter Cardiovasc Interv"},{"issue":"5","key":"3035_CR6","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1111\/1755-5922.12023","volume":"31","author":"M Vavuranakis","year":"2013","unstructured":"Vavuranakis M, Kariori M, Voudris V, Kalogeras K, Vrachatis D, Aznaouridis C et al (2013) Predictive factors of vascular complications after transcatheter aortic valve implantation in patients treated with a default percutaneous strategy. Cardiovasc Ther 31(5):e46-54","journal-title":"Cardiovasc Ther"},{"issue":"1","key":"3035_CR7","first-page":"169","volume":"103","author":"V Androshchuk","year":"2024","unstructured":"Androshchuk V, Chehab O, Prendergast B, Rajani R, Patterson T, Redwood S (2024) Computed tomography derived anatomical predictors of vascular access complications following transfemoral transcatheter aortic valve implantation: a systematic review. Catheter Cardiovasc Interv 103(1):169\u2013185","journal-title":"Catheter Cardiovasc Interv"},{"key":"3035_CR8","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jcin.2011.03.019","volume":"4","author":"K Hayashida","year":"2011","unstructured":"Hayashida K, Lef\u00e8vre T, Chevalier B, Hovasse T, Romano M, Garot P et al (2011) Transfemoral aortic valve implantation new criteria to predict vascular complications. JACC Cardiovasc Interv 4:851\u2013858","journal-title":"JACC Cardiovasc Interv"},{"issue":"5","key":"3035_CR9","first-page":"844","volume":"84","author":"A Krishnaswamy","year":"2014","unstructured":"Krishnaswamy A, Parashar A, Agarwal S, Modi DK, Poddar KL, Svensson LG et al (2014) Predicting vascular complications during transfemoral transcatheter aortic valve replacement using computed tomography: a novel area-based index. Catheter Cardiovasc Interv 84(5):844\u2013851","journal-title":"Catheter Cardiovasc Interv"},{"issue":"1","key":"3035_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.5152\/AnatolJCardiol.2021.147","volume":"26","author":"S \u00c7akal","year":"2022","unstructured":"\u00c7akal S, \u00c7akal B, Karaca O, G\u00fcler Y, \u00d6zcan \u00d6U, G\u00fcne\u015f HM et al (2022) Vascular complications after transcatheter transfemoral aortic valve implantation: modified sheath-to-femoral artery ratio as a new predictor. Anatol J Cardiol 26(1):49\u201356","journal-title":"Anatol J Cardiol"},{"issue":"1","key":"3035_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jcct.2018.10.009","volume":"13","author":"Y Hammer","year":"2019","unstructured":"Hammer Y, Landes U, Zusman O, Kornowski R, Witberg G, Orvin K et al (2019) Iliofemoral artery lumen volume assessment with three dimensional multi-detector computed tomography and vascular complication risk in transfemoral transcatheter aortic valve replacement. J Cardiovasc Comput Tomogr 13(1):68\u201374","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"3035_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.amjcard.2020.12.089","volume":"145","author":"E Durand","year":"2021","unstructured":"Durand E, Penso M, Hemery T, Levesque T, Moles G, Tron C et al (2021) Standardized measurement of femoral artery depth by computed tomography to predict vascular complications after transcatheter aortic valve implantation. Am J Cardiol 145:119\u201327","journal-title":"Am J Cardiol"},{"key":"3035_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.114.001995","author":"K Okuyama","year":"2015","unstructured":"Okuyama K, Jilaihawi H, Kashif M, Takahashi N, Chakravarty T, Pokhrel H et al (2015) Transfemoral access assessment for transcatheter aortic valve replacement: evidence-based application of computed tomography over invasive angiography. Circ Cardiovasc Imaging. https:\/\/doi.org\/10.1161\/CIRCIMAGING.114.001995","journal-title":"Circ Cardiovasc Imaging"},{"issue":"6","key":"3035_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13491","volume":"51","author":"M Mach","year":"2021","unstructured":"Mach M, Poschner T, Hasan W, Szalkiewicz P, Andreas M, Winkler B et al (2021) The Iliofemoral tortuosity score predicts access and bleeding complications during transfemoral transcatheter aortic valve replacement: DataData from the VIenna Cardio Thoracic aOrtic valve registrY (VICTORY). Eur J Clin Invest 51(6):e13491","journal-title":"Eur J Clin Invest"},{"issue":"7","key":"3035_CR15","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.cjco.2022.03.006","volume":"4","author":"A Lux","year":"2022","unstructured":"Lux A, M\u00fcllenberg L, Veenstra LF, Dohmen W, Kats S, Maesen B et al (2022) Iliofemoral tortuosity increases the risk of access-site-related complications after aortic valve implantation and plug-based access-site closure. CJC Open 4(7):609\u2013616","journal-title":"CJC Open"},{"issue":"1","key":"3035_CR16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.amjcard.2019.03.043","volume":"124","author":"J Urbach","year":"2019","unstructured":"Urbach J, Hou CR, Lesser JR, Stanberry LI, Garberich RF, Caye D et al (2019) Computed tomographic angiography-derived risk factors for vascular complications in percutaneous transfemoral transcatheter aortic valve implantation. Am J Cardiol 124(1):98\u2013104","journal-title":"Am J Cardiol"},{"issue":"11","key":"3035_CR17","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.jvir.2010.07.008","volume":"21","author":"TG Walker","year":"2010","unstructured":"Walker TG, Kalva SP, Yeddula K, Wicky S, Kundu S, Drescher P et al (2010) Clinical practice guidelines for endovascular abdominal aortic aneurysm repair: written by the Standards of Practice Committee for the Society of Interventional Radiology and endorsed by the Cardiovascular and Interventional Radiological Society of Europe and the Canadian Interventional Radiology Association. J Vasc Interv Radiol 21(11):1632\u20131655","journal-title":"J Vasc Interv Radiol"},{"key":"3035_CR18","doi-asserted-by":"publisher","DOI":"10.1177\/15266028231172375","author":"L Jordano","year":"2023","unstructured":"Jordano L, Robinson EC, Mirza A, Skeik N, Stanberry L, Manunga J (2023) Effects of iliac tortuosity index on fenestrated endovascular aortic aneurysm repair for pararenal and thoracoabdominal aortic aneurysms. J Endovasc Ther. https:\/\/doi.org\/10.1177\/15266028231172375","journal-title":"J Endovasc Ther"},{"issue":"3","key":"3035_CR19","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jvs.2022.01.142","volume":"76","author":"C Fenelli","year":"2022","unstructured":"Fenelli C, Gargiulo M, Prendes CF, Faggioli G, Stavroulakis K, Gallitto E et al (2022) Effect of iliac tortuosity on outcomes after iliac branch procedures. J Vasc Surg 76(3):714\u201323.e1","journal-title":"J Vasc Surg"},{"issue":"4","key":"3035_CR20","first-page":"121","volume":"29","author":"H Lee","year":"2013","unstructured":"Lee H, Choi J, Han Y, Cho Y-P, Kwon T-W (2013) Tortuosity index and angulation of the common iliac artery in abdominal aortic aneurysm patients treated with the endovascular technique to provide adequate access route. Korean J Vasc Endovasc Surg 29(4):121\u2013127","journal-title":"Korean J Vasc Endovasc Surg"},{"issue":"19","key":"3035_CR21","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1093\/eurheartj\/ehaa799","volume":"42","author":"P G\u00e9n\u00e9reux","year":"2021","unstructured":"G\u00e9n\u00e9reux P, Piazza N, Alu MC, Nazif T, Hahn RT, Pibarot P et al (2021) Valve academic research consortium 3: updated endpoint definitions for aortic valve clinical research. Eur Heart J 42(19):1825\u201357","journal-title":"Eur Heart J"},{"issue":"1","key":"3035_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03231-9","volume":"19","author":"X Luta","year":"2024","unstructured":"Luta X, Zanchi F, Fresa M, Porceddu E, Keller S, Bouchardy J et al (2024) Tortuosity in non-atherosclerotic vascular diseases is associated with age, arterial aneurysms, and hypertension. Orphanet J Rare Dis 19(1):227","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"3035_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1177\/000331979804900505","volume":"49","author":"L Del Corso","year":"1998","unstructured":"Del Corso L, Moruzzo D, Conte B, Agelli M, Romanelli AM, Pastine F et al (1998) Tortuosity, kinking, and coiling of the carotid artery: expression of atherosclerosis or aging? Angiology 49(5):361\u2013371","journal-title":"Angiology"},{"issue":"12","key":"3035_CR24","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.jacc.2012.07.003","volume":"60","author":"P G\u00e9n\u00e9reux","year":"2012","unstructured":"G\u00e9n\u00e9reux P, Webb JG, Svensson LG, Kodali SK, Satler LF, Fearon WF et al (2012) Vascular complications after transcatheter aortic valve replacement: insights from the PARTNER (Placement of AoRTic TraNscathetER Valve) trial. J Am Coll Cardiol 60(12):1043\u20131052","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"3035_CR25","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMoa1816885","volume":"380","author":"JJ Popma","year":"2019","unstructured":"Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O\u2019Hair D et al (2019) Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 380(18):1706\u20131715","journal-title":"N Engl J Med"},{"issue":"6","key":"3035_CR26","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/j.jvs.2020.03.035","volume":"72","author":"Q Langouet","year":"2020","unstructured":"Langouet Q, Martinez R, Saint-Etienne C, Behlaj Soulami R, Harmouche M, Aupart M et al (2020) Incidence, predictors, impact, and treatment of vascular complications after transcatheter aortic valve implantation in a modern prospective cohort under real conditions. J Vasc Surg 72(6):2120\u20139.e2","journal-title":"J Vasc Surg"},{"issue":"9","key":"3035_CR27","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.carrev.2020.01.007","volume":"21","author":"W Batchelor","year":"2020","unstructured":"Batchelor W, Patel K, Hurt J, Totten J, Burroughs P, Smith G et al (2020) Incidence, prognosis and predictors of major vascular complications and percutaneous closure device failure following contemporary percutaneous transfemoral transcatheter aortic valve replacement. Cardiovasc Revasc Med 21(9):1065\u20131073","journal-title":"Cardiovasc Revasc Med"},{"key":"3035_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.carrev.2021.08.004","volume":"38","author":"Y Honda","year":"2022","unstructured":"Honda Y, Yamawaki M, Nakano T, Makino K, Ito Y, Yashima F et al (2022) Successfully managed access-site complication was not associated with worse outcome after percutaneous transfemoral transcatheter aortic valve implantation: up-to-date insights from the OCEAN-TAVI Registry. Cardiovasc Revasc Med 38:11\u201318","journal-title":"Cardiovasc Revasc Med"},{"key":"3035_CR29","doi-asserted-by":"crossref","unstructured":"Sherwood MW, Xiang K, Matsouaka R, Li Z, Vemulapalli S, Vora AN, et al. Incidence, temporal trends, and associated outcomes of vascular and bleeding complications in patients undergoing transfemoral transcatheter aortic valve replacement. Circulation: Cardiovascular Interventions. 2020;13(1):e008227.","DOI":"10.1161\/CIRCINTERVENTIONS.119.008227"},{"issue":"16","key":"3035_CR30","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1161\/CIRCULATIONAHA.124.071838","volume":"151","author":"AM Vekstein","year":"2025","unstructured":"Vekstein AM, Wegermann ZK, Manandhar P, Mack MJ, Cohen DJ, Hughes GC et al (2025) Outcomes of transcatheter aortic valve replacement in low-risk patients in the United States: a report from the STS\/ACC TVT registry. Circulation 151(16):1134\u20131146","journal-title":"Circulation"},{"issue":"36","key":"3035_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccas.2025.105614","volume":"30","author":"ML Theriot","year":"2025","unstructured":"Theriot ML, Bergen EC, Lugo JG, Graham WM (2025) Reducing TAVR vascular complications through multidisciplinary process optimization. JACC Case Rep 30(36):105614","journal-title":"JACC Case Rep"},{"key":"3035_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.amjcard.2020.10.035","volume":"139","author":"JM Michel","year":"2021","unstructured":"Michel JM, Hashorva D, Kretschmer A, Alvarez-Covarrubias HA, Mayr NP, Pellegrini C et al (2021) Evaluation of a low-dose radiation protocol during transcatheter aortic valve implantation. Am J Cardiol 139:71\u201378","journal-title":"Am J Cardiol"},{"issue":"7","key":"3035_CR33","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/eurheartj\/ehae784","volume":"46","author":"T Rheude","year":"2025","unstructured":"Rheude T, Ruge H, Altaner N, Pellegrini C, Alvarez Covarrubias H, Mayr P et al (2025) Comparison of strategies for vascular ACCESS closure after transcatheter aortic valve implantation: the ACCESS-TAVI randomized trial. Eur Heart J 46(7):635\u201345","journal-title":"Eur Heart J"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-03035-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-026-03035-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-03035-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:02:46Z","timestamp":1790892166000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-026-03035-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":33,"alternative-id":["3035"],"URL":"https:\/\/doi.org\/10.1007\/s00392-026-03035-w","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"17 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hector A. Alvarez-Covarrubias received lecture fees from SIS Medical AG, Translumina, LifeTech, and Edward Lifesciences, not related to the current work. Masaru Seguchi received lecture fees from Novartis Pharma, Amgen, Nipro, Biotronik, Dai-ichi Sankyo, Kowa, and Kaneka Medics, not related to the current work. Dr. Rheude received speaker fees from AstraZeneca, Boston Scientific, Edwards Lifesciences, SIS Medical AG, Terumo, and Translumina and travel support from Abbott, Boehringer Ingelheim, Edwards Lifesciences, LifeTech, and SIS Medical AG, outside the submitted work. Erion Xhepa reports lecture fees from Astra Zeneca, Boston Scientific, and SIS Medical and financial support from Abbott Vascular, not related to the current work. Michael Joner reports personal fees from Abbott, Alchimedics S.A.S., Astra Zeneca, Biotronik, Medtronic, Recor, Shockwave, TriCares, and Veryan, grants and personal fees from Boston Scientific, Cardiac Dimensions, and Edwards, grant from Infraredx outside the submitted work. The rest of the authors have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}